Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Testosterone Cypionate Injection 100mg/ml and 200mg/ml from the United States Food and Drug Administration (US FDA).
Cipla's Testosterone Cypionate Injection 100mg/ml and 200mg/ml is AO-rated generic therapeutic equivalent version of Pharmacia and Upjohn's Depo-Testosterone®. It is indicated for replacement therapy in males in conditions associated with symptoms of deficiency or absence of endogenous testosterone.
According to IQVIA (IMS Health), Depo-Testosterone® and its generic
equivalents had US sales of approximately $191M for the 12-month period
ending April 2018.
The product is available for shipping immediately.